KAPA KAIROS PHARMA LTD revenue, earnings and financials
For the quarter ended June 30, 2026, KAIROS PHARMA LTD reported revenue of n/a, net income of −$1.39M and diluted EPS of −$0.06; for the fiscal year ended December 2025 revenue was n/a.
KAPA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$5.57M, net income −$5.45M (margin n/a), EPS −$0.30
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$2.34M, net income −$2.60M (margin n/a), EPS −$0.23
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$1.71M, net income −$1.81M (margin n/a), EPS −$0.17
KAPA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$1.39M, EPS −$0.06
- Quarter ended Mar 31, 2026: revenue n/a, net income −$1.65M, EPS −$0.08
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$1.37M, EPS −$0.07
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.40M, EPS −$0.07
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.42M, EPS −$0.08
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.26M, EPS −$0.08
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$980K, EPS −$0.08
- Quarter ended Sep 30, 2024: revenue n/a, net income −$1.05M, EPS −$0.10
- Quarter ended Jun 30, 2024: revenue n/a, net income −$253K, EPS −$0.02
- Quarter ended Mar 31, 2024: revenue n/a, net income −$323K, EPS −$0.03
- Quarter ended Sep 30, 2023: revenue n/a, net income −$312K, EPS −$0.03
KAPA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$3.44M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$3.96M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $81.0K, share buybacks n/a
KAPA balance sheet
- Jun 30, 2026: cash $2.63M, total assets $4.46M, total liabilities n/a, shareholders' equity $4.19M
- Mar 31, 2026: cash $3.68M, total assets $5.74M, total liabilities n/a, shareholders' equity $5.31M
- Dec 31, 2025: cash $4.49M, total assets $6.54M, total liabilities n/a, shareholders' equity $6.34M
- Sep 30, 2025: cash $5.58M, total assets $8.07M, total liabilities n/a, shareholders' equity $7.66M
- Jun 30, 2025: cash $3.03M, total assets $6.67M, total liabilities n/a, shareholders' equity $6.00M
- Mar 31, 2025: cash $3.62M, total assets $7.94M, total liabilities n/a, shareholders' equity $7.13M
- Dec 31, 2024: cash $1.27M, total assets $5.77M, total liabilities $992K, shareholders' equity $4.78M
- Sep 30, 2024: cash n/a, total assets $5.00M, total liabilities $1.67M, shareholders' equity $3.33M
Is KAPA profitable?
No. KAIROS PHARMA LTD lost $5.81M over the last four quarters.
What is KAPA's EPS?
Diluted earnings per share over the last four quarters were −$0.28; −$0.06 in the latest quarter.